Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Front Aging ; 4: 1258184, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-38500495

RESUMO

Changes in DNA methylation patterning have been reported to be a key hallmark of aged human skin. The altered DNA methylation patterns are correlated with deregulated gene expression and impaired tissue functionality, leading to the well-known skin aging phenotype. Searching for small molecules, which correct the aged methylation pattern therefore represents a novel and attractive strategy for the identification of anti-aging compounds. DNMT1 maintains epigenetic information by copying methylation patterns from the parental (methylated) strand to the newly synthesized strand after DNA replication. We hypothesized that a modest inhibition of this process promotes the restoration of the ground-state epigenetic pattern, thereby inducing rejuvenating effects. In this study, we screened a library of 1800 natural substances and 640 FDA-approved drugs and identified the well-known antioxidant and anti-inflammatory molecule dihydromyricetin (DHM) as an inhibitor of the DNA methyltransferase DNMT1. DHM is the active ingredient of several plants with medicinal use and showed robust inhibition of DNMT1 in biochemical assays. We also analyzed the effect of DHM in cultivated keratinocytes by array-based methylation profiling and observed a moderate, but significant global hypomethylation effect upon treatment. To further characterize DHM-induced methylation changes, we used published DNA methylation clocks and newly established age predictors to demonstrate that the DHM-induced methylation change is associated with a reduction in the biological age of the cells. Further studies also revealed re-activation of age-dependently hypermethylated and silenced genes in vivo and a reduction in age-dependent epidermal thinning in a 3-dimensional skin model. Our findings thus establish DHM as an epigenetic inhibitor with rejuvenating effects for aged human skin.

2.
Biom J ; 47(1): 82-7; discussion 99-107, 2005 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16395999

RESUMO

Statistical analysis plays a fundamental part in the evaluation of mutagenicity experiments. However, a statistically significant or non-significant test result without incorporating the biological relevance cannot be a valid scientific criterion for concluding a positive or negative effect of the underlying compound (Hauschke et al., 1997). The classification of an experiment as being negative or positive should be based also on the magnitude of the responses in the positive control. We address the problem of determining the maximum safe dose by incorporating a biologically meaningful threshold value, which is expressed as a fraction of the difference between positive and vehicle control.


Assuntos
Biometria/métodos , Ensaios Clínicos Controlados como Assunto/métodos , Interpretação Estatística de Dados , Avaliação de Medicamentos , Testes de Mutagenicidade/métodos , Pesquisa , Equivalência Terapêutica , Biofarmácia/métodos , Intervalos de Confiança , Ensaios Clínicos Controlados como Assunto/estatística & dados numéricos , Tratamento Farmacológico , Guias como Assunto , Dose Máxima Tolerável
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...